NCT06330012 The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
| NCT ID | NCT06330012 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | HER2-positive Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-03-18 |
| Primary Completion | 2025-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-03-18 with a primary completion date of 2025-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Eligibility Criteria
Inclusion Criteria: * HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples Exclusion Criteria: * TNBC breast cancer * Hormone receptor positive breast cancer * Non-available FFPE samples * Treated except T-Dxd
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06330012 clinical trial?
This trial is open to female participants only, studying HER2-positive Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06330012 currently recruiting?
Yes, NCT06330012 is actively recruiting participants. Contact the research team at jyeon25@skku.edu for enrollment information.
Where is the NCT06330012 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06330012 clinical trial?
NCT06330012 is sponsored by Samsung Medical Center. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.